ACETYLCYSTEINE INJECTION DIN 02528274
Health Canada record
| Active ingredient(s) | ACETYLCYSTEINE 200 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | R05CB01 ACETYLCYSTEINE |
| Original market date | |
| Current status date | 20-Jun-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Auro Pharma Inc — licence 101305, currently licensed, last inspection rating C (2023-09-27).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ACETYLCYSTEINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02534908 | ACETYLCYSTEINE INJECTION | EUGIA PHARMA INC. | Solution | ACETYLCYSTEINE 200 MG | Approved |
| 02243098 | ACETYLCYSTEINE SOLUTION | SANDOZ CANADA INCORPORATED | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02538431 | ACETYLCYSTEINE SOLUTION USP | STERIMAX INC | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02459906 | ACETYLCYSTEINE SOLUTION USP | HIKMA CANADA LIMITED | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02300435 | ACETYLCYSTEINE INJECTION | TELIGENT OU | Solution | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 02091526 | MUCOMYST | WELLSPRING PHARMACEUTICAL CANADA CORP | Solution | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 00606235 | MUCOMYST INJ 200MG/ML | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Liquid | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 02181460 | PARVOLEX | MYLAN PHARMACEUTICALS ULC | Liquid | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 02094738 | PARVOLEX LIQ IV 200MG/ML | BIONICHE PHARMA (CANADA) LTD | Liquid | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28412 | 2022-06-20 | Abbreviated New Drug Submission (ANDS) |
International API supply for ACETYLCYSTEINE
11 valid EDQM Certificates of Suitability from 10 holders. 7 active FDA Drug Master Files.
Request a quote for ACETYLCYSTEINE INJECTION